TICKERNERD
Menu
KIDSKIDSHealthcare · Medical Devices

KIDS Stock Forecast: OrthoPediatrics Corp. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$22
+2.32% on the day

The 9 Wall Street analysts covering OrthoPediatrics Corp. hold a median 12-month price target of $25 — +13.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 65 of 100 as at 12 Sept 2026 — in the upper half.

Market cap
$576.0M
Ticker Nerd rank
65 / 100
Median analyst target
$25
Analysts covering
9
Revenue$70.5M+15.4% y/y
Operating income−$4.1M
Net income−$7.2M
Free cash flow−$3.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.3%
1M
−9.0%
YTD
+24.2%
1Y
+8.5%
From 52W high
−16.8%
From 52W low
+50.7%
$15
$27
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

KIDS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores OrthoPediatrics Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
65 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
83
Accruals
70
Momentum
65
Volatility
62
Value
59
Quality
53
Size
52
Revisions
51
Issuance
31

Growth (83): Sales and profits are climbing, and climbing faster than before.

Issuance (31): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

KIDS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KIDS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$15$20$25$30$35Oct 25Jan 26Apr 26Jul 26KIDSHigh $35Median $25Low $22

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
8 Buy1 Hold0 Sell
Low $22Median $25High $35

The green dot is the last close — the median target sits +13.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
20 Aug 2026BTIGMaintainsBuy$24 → $29
5 Aug 2026NeedhamMaintainsBuy—
5 Aug 2026NeedhamMaintainsBuy$30 → $35
5 Aug 2026Piper SandlerReiteratesOverweight—
5 Aug 2026Piper SandlerReiteratesOverweight$22 → $25
16 July 2026Truist SecuritiesMaintainsHold—
16 July 2026Truist SecuritiesMaintainsHold$17 → $20
1 May 2026BTIGReiteratesBuy—
1 May 2026BTIGReiteratesBuy$24
2 Mar 2026Truist SecuritiesMaintainsHold—
27 Feb 2026BTIGMaintainsBuy—
27 Feb 2026NeedhamMaintainsBuy—
27 Jan 2026TD CowenInitiatesBuy—
10 Dec 2025Canaccord GenuityInitiatesBuy—
29 Oct 2025BTIGReiteratesBuy—
29 Oct 2025NeedhamMaintainsBuy—
10 Oct 2025BTIGMaintainsBuy—
10 Oct 2025JMP SecuritiesMaintainsMarket Outperform—
10 Oct 2025Lake StreetMaintainsBuy—
10 Oct 2025Piper SandlerMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KIDS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

KIDS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, OrthoPediatrics Corp. returned +8.5% against +17.5% for the S&P 500, dividends included.

KIDS vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120130Oct 25Jan 26Apr 26Jul 26KIDSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

KIDS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
2
Fundamentals

OrthoPediatrics Corp. (KIDS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
246.3×

Cheaper than 3% of US stocks

Price / sales
2.3×

Cheaper than 49% of US stocks

Price / book
1.7×

Cheaper than 51% of US stocks

EV / EBITDA
−1441.1×

Cheaper than 99% of US stocks

Growth & margins
Revenue growth (YoY)
15.4%

Higher than 63% of US stocks

Earnings growth (YoY)
15.4%

Higher than 53% of US stocks

Gross margin
74.3%

Higher than 87% of US stocks

Operating margin
−5.8%

Higher than 27% of US stocks

Net margin
−15.7%

Higher than 17% of US stocks

Returns & dividend
Return on equity
−11.4%

Higher than 35% of US stocks

Return on assets
−2.8%

Higher than 35% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

OrthoPediatrics Corp. (KIDS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • OrthoPediatrics Corp. has a market value of $576.0M and an enterprise value of $641.3M.

  • Revenue in the twelve months to 30 June 2026: $252.7M. The latest quarter grew 15.4% year on year.

  • Net income over the same four quarters: −$39.7M, a −15.7% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.68.

  • Free cash flow in the twelve months to 30 June 2026: −$1.8M.

  • Shares outstanding: 26.1M.

  • Trailing P/E: 246.3×; forward P/E: −31.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • OrthoPediatrics Corp. employs 602 people — $420K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

KIDS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
KIDSOrthoPediatrics Corp.$576.0M
65
DCTHDelcath Systems, Inc.$549.2M
96
CTKBCytek Biosciences, Inc.$595.3M
64
TCMDTactile Systems Technology, Inc.$505.3M
97
CERSCerus Corp.$478.3M
91
SSIISS Innovations International, Inc.$640.9M
21
NPCENeuroPace, Inc.$472.7M
92

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own OrthoPediatrics Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KIDS news & analysis

OrthoPediatrics Announces Full Commercial Launch of 3P™ Pediatric Plating Platform® Hip System Following More Than 350 Successful Implantations

GlobeNewsWire · 25 Aug 2026positive

OrthoPediatrics announced the full commercial launch of its 3P Pediatric Plating Platform Hip System, following a successful limited launch with more than 350 implantations. The launch reflects demand for the company's pediatric-specific hip plating technology.

Why it matters — This marks the transition of a new pediatric-specific hip product to wider commercial availability, expanding OrthoPediatrics' core product lineup.

OrthoPediatrics Sees ‘Inflection Point' as New Products Fuel Record Quarter

MarketBeat · 14 Aug 2026positive

OrthoPediatrics reported record revenue, adjusted EBITDA and number of children helped in Q2, with CEO Dave Bailey noting at the Canaccord Genuity Growth Conference that the company is seeing early contributions from its newer "super cycle" products, marking an inflection point.

Why it matters — The record results and early contributions from new "super cycle" products signal that OrthoPediatrics may be entering a period of accelerated growth, which is important for investors watching the company's trajectory.

OrthoPediatrics Corp. (KIDS) Q2 2026 Earnings Call Transcript

Seeking Alpha · 5 Aug 2026neutral

Seeking Alpha published a transcript of OrthoPediatrics Corp.'s (KIDS) Q2 2026 earnings call, covering the company's quarterly update. The transcript documents the company's earnings call proceedings for that quarter.

Why it matters — A KIDS watcher can review the full earnings call transcript for management commentary on the company's second-quarter results.

OrthoPediatrics Q2 Earnings Call Highlights

MarketBeat · 5 Aug 2026positive

OrthoPediatrics reported record second-quarter revenue of $70.5 million, a 15% year-over-year increase, driven by strong Trauma & Deformity and specialty bracing results despite a decline in scoliosis revenue. The company also raised its 2026 revenue outlook while maintaining its adjusted EBITDA and free-cash-flow targets.

Why it matters — The record revenue and raised outlook signal stronger-than-expected operational performance and management's confidence in the company's growth trajectory.

OrthoPediatrics (KIDS) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 5 Aug 2026neutral

OrthoPediatrics reported a Q2 loss of $0.26 per share, which was narrower than the Zacks Consensus Estimate of a $0.31 loss but wider than the $0.11 loss per share it posted a year earlier. The headline notes the company topped revenue estimates for the quarter.

Why it matters — KIDS watchers would care because the company's quarterly results beat analyst expectations despite a year-over-year widening of its loss.

FAQ

Frequently asked questions about KIDS stock

What is the KIDS stock price forecast for 2026-2027?

The 9 Wall Street analysts covering OrthoPediatrics Corp. have a median 12-month price target of $25, with estimates ranging from $22 to $35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KIDS stock a buy right now?

Of the 9 analysts covering OrthoPediatrics Corp., 8 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks OrthoPediatrics Corp. 65 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KIDS?

As at 12 Sept 2026, OrthoPediatrics Corp. ranks 65 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (83 of 100).

Will KIDS stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +13.3% from the last close, and Ticker Nerd's factor model ranks OrthoPediatrics Corp. 65 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KIDS stock forecast for 2030?

No analyst covering OrthoPediatrics Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KIDS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $35 over the next 12 months.

How has KIDS stock performed over the past year?

OrthoPediatrics Corp. returned +8.5% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does OrthoPediatrics Corp. do?

OrthoPediatrics Corp. is a medical device company focused exclusively on pediatric orthopedics.

What is the latest news on KIDS?

The most recent item we track (GlobeNewsWire, 25 Aug 2026): "OrthoPediatrics Announces Full Commercial Launch of 3P™ Pediatric Plating Platform® Hip System Following More Than 350 Successful Implantations". OrthoPediatrics announced the full commercial launch of its 3P Pediatric Plating Platform Hip System, following a successful limited launch with more than 350 implantations. The launch reflects demand for the company's pediatric-specific hip plating technology.

Company

About OrthoPediatrics Corp.

OrthoPediatrics Corp. is a medical device company focused exclusively on pediatric orthopedics. It designs, develops, and markets anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions, supporting surgeons and caregivers in treating trauma and deformity correction, scoliosis, and sports medicine cases. The company’s product portfolio includes surgical systems, pediatric nailing solutions, spinal care products, and specialty bracing technologies tailored to the needs of smaller and developing patients. OrthoPediatrics also operates orthopedic and prosthetic clinic services, extending its role beyond products to non-surgical care. Its business is centered on serving hospitals, children’s medical centers, and orthopedic specialists in the United States and international markets. Headquartered in Warsaw, Indiana, OrthoPediatrics occupies a specialized position in the medical technology market as a pediatric-only orthopedic platform.

CEO Mr. David R. Bailey · 602 employees · United States · https://www.orthopediatrics.com